Oncology and hematology

腫瘍・血液内科について

最新年度業績

2024年

  1. Shimoyama R, Imamura Y, Uryu K, Mase T, Taguri M, Okuda T, Fujimura Y, Hayashi M, Tanaka S, Sawamukai K, Minami H. Real-world treatment outcomes of metastatic biliary tract cancer patients in Japan: the Tokushukai REAl-world data project 04 (TREAD 04).Jpn J Clin Oncol. 2024 Jan 7;54(1):70-80. doi: 10.1093/jjco/hyad133.


    https://pubmed.ncbi.nlm.nih.gov/37801431/

  2. Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Horiuchi S, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Tsuya A, Fukuoka M, Minami H. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).Jpn J Clin Oncol. 2024 Mar 9;54(3):319-328. doi: 10.1093/jjco/hyad162.


    https://pubmed.ncbi.nlm.nih.gov/37997468/

  3. Kitahiro Y, Yamamoto K, Yakushijin K, Ioroi T, Tanda M, Itohara K, Omura T, Minami H, Yano I. The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial.JMIR Res Protoc . 2024 Feb 22:13:e54882. doi: 10.2196/54882.


    https://pubmed.ncbi.nlm.nih.gov/38386393/

  4. Ichikawa H, Yakushijin K, Kurata K, Tsuji T, Takemoto N, Joyce M, Okazoe Y, Takahashi R, Matsumoto S, Sakai R, Kitao A, Miyata Y, Saito Y, Kawamoto S, Yamamoto K, Ito M, Murayama T, Matsuoka H, Minami H. Utility of the refined EBMT diagnostic and severity criteria 2023 for sinusoidal obstruction syndrome/veno-occlusive disease. Bone Marrow Transplant. 2024 Apr;59(4):518-525. doi: 10.1038/s41409-024-02215-4. Epub 2024 Jan 29.


    https://pubmed.ncbi.nlm.nih.gov/38287083/

  5. Onozawa M, Kusumoto S, Najima Y, Hashimoto H, Okada K, Tamaki M, Tanaka M, Sato T, Takahashi T, Hatano K, Onodera K, Moriuchi Y, Yakushijin K, Kanda J, Nagafuji K, Ogata M, Nakano N, Tamori A, Mizokami M. Outcomes of Cessation of Nucleos(t)ide Analog Administration on Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation: A Nationwide Retrospective Study.Transplant Cell Ther. 2024 Mar;30(3):330.e1-330.e8. doi: 10.1016/j.jtct.2024.01.059. Epub 2024 Jan 17.


    https://pubmed.ncbi.nlm.nih.gov/38242442/

  6. Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka KI, Maruyama Y, Ota S, Ishikawa J, Kawakita T, Akasaka T, Kamimura T, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.Br J Haematol. 2024 Mar;204(3):959-966. doi: 10.1111/bjh.19228. Epub 2023 Nov 30.


    https://pubmed.ncbi.nlm.nih.gov/38037468/

  7. Okada Y, Usui Y, Hayashi H, Nishikubo M, Toubai T, Uchida N, Tanaka M, Onizuka M, Takahashi S, Doki N, Uehara Y, Maruyama Y, Ishiwata K, Kawakita T, Sawa M, Eto T, Ishimaru F, Kato K, Fukuda T, Atsuta Y, Kanda J, Yakushijin K, Nakasone H. Development of an umbilical cord blood transplantation-specific nonrelapse mortality risk assessment score.Blood Adv. 2024 Mar 26;8(6):1359-1368. doi: 10.1182/bloodadvances.2023011837.


    https://pubmed.ncbi.nlm.nih.gov/38163321/

  8. Nishikage S, Fujisawa A, Endoh H, Sakamoto H, Suzuki T, Kanzawa M, Ishii S, Okano M, Nitta E, Yakushijin K, Asakura H, Nozu K, Nitta R, Katayama Y, Sakaguchi K. Amyloid deposition through endocytosis in vascular endothelial cells.Exp Hematol. 2024 Jan:129:104129. doi: 10.1016/j.exphem.2023.11.003. Epub 2023 Nov 10.


    https://pubmed.ncbi.nlm.nih.gov/37952890/

  9. Homma A, Ando M, Hanai N, Harada H, Honma Y, Kanda T, Kano S, Kawakita D, Kiyota N, Kizawa Y, Nakagawa M, Ogawa T, Shinomiya H, Shinozaki T, Suzuki M, Tsuji T, Yasuda K, Zenda S, Kodaira T, Kirita T, Nibu KI. Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer. Auris Nasus Larynx. 2024 Feb;51(1):174-188. doi: 10.1016/j.anl.2023.07.003. Epub 2023 Jul 21.


    https://pubmed.ncbi.nlm.nih.gov/37482431/

  10. Ariizumi Y, Hanai N, Asakage T, Seto A, Tomioka T, Miyabe J, Kessoku H, Mukaigawa T, Omura G, Teshima M, Nishikawa D, Saito Y, Asada Y, Fujisawa T, Makino T, Nishino H, Sano D, Nakahira M, Tokashiki K, Uemura H, Ueda T, Sakai A, Masuda M, Tsujikawa T, Hiei Y, Nishio N, Matsui H, Kiyota N, Homma A. Extent of thyroidectomy and paratracheal lymph node dissection in total pharyngolaryngectomy for pyriform sinus cancer, and recurrence, survival, and postoperative hypoparathyroidism: A multicenter retrospective study.Head Neck. 2024 Feb;46(2):269-281. doi: 10.1002/hed.27572. Epub 2023 Nov 13.


    https://pubmed.ncbi.nlm.nih.gov/37955187/

  11. Kajimoto Y, Shinomiya H, Uehara N, Teshima M, Fujita T, Kakigi A, Imamura Y, Kiyota N, Miyawaki D, Sasaki R, Kimura H, Nibu KI. Expression of EGFR and p16 in Squamous Cell Carcinoma of External Auditory Canal.2024 Jan 31;69(4):E144-E150. doi: 10.24546/0100486232.


    https://pubmed.ncbi.nlm.nih.gov/38379276/

  12. Kiyota N, Tahara M, Homma A. Current status and future perspective of postoperative treatment for locally advanced squamous cell carcinoma of the head and neck.Jpn J Clin Oncol. 2024 Jun 1;54(6):613-619. doi: 10.1093/jjco/hyae029.


    https://pubmed.ncbi.nlm.nih.gov/38452121/

  13. Tahara M, Kiyota N, Imai H, Takahashi S, Nishiyama A, Tamura S, Shimizu Y, Kadowaki S, Ito KI, Toyoshima M, Hirashima Y, Ueno S, Sugitani I. A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic BRAF-Mutated Thyroid Cancer in Japan.Thyroid 2024 Apr;34(4):467-476. doi: 10.1089/thy.2023.0547. Epub 2024 Mar 14.


    https://pubmed.ncbi.nlm.nih.gov/38343359/

  14. Taylor KJ, Amdal CD, Bjordal K, Astrup GL, Herlofson BB, Duprez F, Gama RR, Jacinto A, Hammerlid E, Scricciolo M, Jansen F, Verdonck-de Leeuw IM, Fanetti G, Guntinas-Lichius O, Inhestern J, Dragan T, Fabian A, Boehm A, Wöhner U, Kiyota N, Krüger M, Bonomo P, Pinto M, Nuyts S, Silva JC, Stromberger C, Specenier P, Tramacere F, Bushnak A, Perotti P, Plath M, Paderno A, Stempler N, Kouri M, Grégoire V, Singer S; EORTC Quality of Life Group and the EORTC Head and Neck Group. Long-term health-related quality of life in head and neck cancer survivors: A large multinational study.Int J Cancer. 2024 May 15;154(10):1772-1785. doi: 10.1002/ijc.34861. Epub 2024 Feb 5.


    https://pubmed.ncbi.nlm.nih.gov/38312044/

  15. Uryu K, Imamura Y, Shimoyama R, Mase T, Fujimura Y, Hayashi M, Ohtaki M, Otani K, Hibino M, Shigeto H, Fukui T, Fukai R, Chihara Y, Iwase A, Yamada N, Tamura Y, Harada H, Shinozaki N, Shimada T, Tsuya A, Fukuoka M, Minami H. Prognostic impact of concomitant pH-regulating drugs in patients with non-small cell lung cancer receiving epidermal growth factor receptor tyrosine kinase inhibitors: the Tokushukai REAl-world Data project 01-S1.Cancer Chemother Pharmacol . 2024 Aug;94(2):197-208. doi: 10.1007/s00280-024-04666-4. Epub 2024 Apr 8.


    https://pubmed.ncbi.nlm.nih.gov/38584202/

  16. Goto H, Oshikiri T, Kato T, Nagatani Y, Funakoshi Y, Koterazawa Y, Sawada R, Harada H, Urakawa N, Hasegawa H, Kanaji S, Yamashita K, Matsuda T, Minami H, Kakeji Y. Protocol for a phase II study to evaluate the efficacy and safety of nivolumab as a postoperative adjuvant therapy for patients with esophageal cancer treated with preoperative docetaxel, cisplatin plus 5-fluorouracil treatment (PENTAGON trial).PLoS One . 2024 Apr 18;19(4):e0299742. doi: 10.1371/journal.pone.0299742. eCollection 2024.


    https://pubmed.ncbi.nlm.nih.gov/38635652/

  17. Koyama T, Kiyota N, Boku S, Imamura Y, Shibata N, Satake H, Tanaka K, Hayashi H, Onoe T, Asada Y, Yamazaki T, Nose T, Ohata S, Nagatani Y, Kimbara S, Funakoshi Y, Teshima N, Shinomiya H, Minami H. A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-PD-1 antibody.ESMO Open. 2024 Jun;9(6):103476. doi: 10.1016/j.esmoop.2024.103476. Epub 2024 Jun 3.


    https://pubmed.ncbi.nlm.nih.gov/38833968/

  18. Yohei Funakoshi, Kimikazu Yakushijin, Goh Ohji, Takaji Matsutani, Kazuhiko Doi, Hironori Sakai, Tomoki Sasaki, Takahiro Kusakabe, Sakuya Matsumoto, Yasuyuki Saito, Shinichiro Kawamoto, Katsuya Yamamoto, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Yoshinori Imamura, Naomi Kiyota, Mitsuhiro Ito, Hironobu Minami Analysis of B-cell receptor repertoire to evaluate immunogenicity of monovalent Omicron XBB.1.5 mRNA vaccines.EJHaem. 2024 May 29;5(4):661-668. doi: 10.1002/jha2.932. eCollection 2024 Aug.


    https://pubmed.ncbi.nlm.nih.gov/39157599/

  19. Nagatani Y, Kiyota N, Imamura Y, Koyama T, Funakoshi Y, Komatsu M, Itoh T, Teshima M, Nibu KI, Sakai K, Nishio K, Shimomura M, Nakatsura T, Ikarashi D, Nakayama T, Kitano S, Minami H. Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer.Asia Pac J Clin Oncol. 2024 Dec;20(6):779-788. doi: 10.1111/ajco.14108. Epub 2024 Sep 4.


    https://pubmed.ncbi.nlm.nih.gov/39233454/

  20. Terao T, Matsuoka KI, Fuji S, Kawamura S, Toya T, Doki N, Uchida N, Tanaka M, Fukuda T, Sawa M, Ishikawa J, Nishida T, Ohigashi H, Maruyama Y, Fujiwara SI, Kanda Y, Ota S, Ishimaru F, Atsuta Y, Kanda J, Ogata M, Yakushijin K, Nakasone H. Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era.Bone Marrow Transplant. 2024 Sep;59(9):1224-1231. doi: 10.1038/s41409-024-02313-3. Epub 2024 May 25.


    https://pubmed.ncbi.nlm.nih.gov/38796633/

  21. Kawamura S, Tamaki M, Konuma T, Onizuka M, Sakaida E, Hayashi H, Doki N, Nishida T, Sawa M, Ohigashi H, Fukuda T, Ishikawa J, Matsuoka KI, Kawakita T, Tanaka M, Ishimaru F, Ichinohe T, Atsuta Y, Kanda Y, Yakushijin K, Kanda J, Nakasone H. Superiority of BM over PBSC for recipients with pre-transplant lung dysfunction in HLA-matched allogeneic HCT.Cytotherapy. 2024 Nov;26(11):1353-1361. doi: 10.1016/j.jcyt.2024.06.006. Epub 2024 Jun 12.


    https://pubmed.ncbi.nlm.nih.gov/38958628/

  22. Kamijo K, Shimomura Y, Kim SW, Ohigashi H, Ishikawa J, Eto T, Hiramoto N, Mizuno I, Iida S, Ueda Y, Matsuoka KI, Yakushijin K, Mori Y, Onizuka M, Fukuda T, Atsuta Y, Kako S. Reduced-intensity conditioning with fludarabine/busulfan versus fludarabine/low-dose melphalan in patients with non-Hodgkin lymphoma undergoing allogeneic haematopoietic stem cell transplantation.Br J Haematol. 2024 Sep;205(3):1097-1107. doi: 10.1111/bjh.19651. Epub 2024 Jul 24.


    https://pubmed.ncbi.nlm.nih.gov/39049594/

  23. Fuji S, Nakamae H, Sugita J, Najima Y, Konishi T, Tanaka T, Nakashima Y, Nishimoto M, Okamura H, Nakayama K, Ito A, Yoshimitsu M, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Lower-dose post-transplant cyclophosphamide in haploidentical hematopoietic cell transplantation.Bone Marrow Transplant. 2024 Nov;59(11):1628-1630. doi: 10.1038/s41409-024-02405-0. Epub 2024 Aug 26.


    https://pubmed.ncbi.nlm.nih.gov/39187600/

  24. Pilz MJ, Seyringer S, Singer S, Ioannidis G, Sykiotis GP, Arraras JI, Husson O, Iakovou I, Fanetti G, Führer D, Inhestern J, Kiyota N, Locati LD, Pinto M, Gama RR, King MT, Norman R, Gamper EM; EORTC Quality of Life Group. The Cancer-Specific Health Economic Measure QLU-C10D is Valid and Responsive for Assessing Health Utility in Patients with Thyroid Cancer.Thyroid. 2024 Nov;34(11):1356-1370. doi: 10.1089/thy.2024.0396. Epub 2024 Oct 30.


    https://pubmed.ncbi.nlm.nih.gov/39475110/

  25. Singer S, Hammerlid E, Tomaszewska IM, Amdal CD, Herlofson BB, Santos M, Castro Silva J, Mehanna H, Fullerton A, Young T, Fernandez Gonzalez L, Inhestern J, Pinto M, Arraras JI, Yarom N, Bonomo P, Baumann I, Galalae R, Nicolatou-Galitis O, Kiyota N, Raber-Durlacher J, Salem D, Fabian A, Boehm A, Krejovic-Trivic S, Chie WC, Taylor KJ, Sherman AC, Licitra L, Machiels JP, Bjordal K;EORTC Quality of Life Group and the EORTC Head and Neck Cancer Group. The european organisation for research and treatment of cancer head and neck cancer module (EORTC QLQ-HN43): Estimates for minimal important difference and minimal important change.Eur J Cancer. 2024 Nov:212:115062. doi: 10.1016/j.ejca.2024.115062. Epub 2024 Oct 9.


    https://pubmed.ncbi.nlm.nih.gov/39405647/

  26. Imamura Y, Kiyota N, Tahara M, Kodaira T, Hayashi R, Nishino H, Asada Y, Mitani H, Iwae S, Nishio N, Onozawa Y, Hanai N, Ohkoshi A, Hara H, Monden N, Nagaoka M, Minami S, Kitabayashi R, Sasaki K, Homma A; Effect of acute kidney injury and overall survival in patients with postoperative head and neck cancer who received chemoradiotherapy with cisplatin: A supplementary analysis of the phase II/III trial of JCOG1008.Cancer Med. 2024 Sep;13(18):e70235. doi: 10.1002/cam4.70235.


    https://pubmed.ncbi.nlm.nih.gov/39348265/

  27. Yokoyama K, Wasano K, Sasaki K, Machida R, Nakahira M, Kitamura K, Sakagami T, Takeshita N, Ohkoshi A, Suzuki M, Tateya I, Morishita Y, Sekimizu M, Nakayama M, Koyama T, Shibata H, Miyamaru S, Kiyota N, Hanai N, Homma A. Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.Jpn J Clin Oncol. 2024 Oct 3;54(10):1115-1122. doi: 10.1093/jjco/hyae117.


    https://pubmed.ncbi.nlm.nih.gov/39206595/

  28. Shimizu H, Kodaira T, Kiyota N, Hayashi R, Nishino H, Asada Y, Mitani H, Hirayama Y, Onozawa Y, Nishio N, Hanai N, Ohkoshi A, Hara H, Monden N, Nagaoka M, Minami S, Fujii T, Tanaka K, Homma A, Yoshimoto S, Oridate N, Omori K, Ueda T, Okami K, Uemura H, Shiga K, Nakahira M, Asakage T, Saito Y, Sasaki K, Kitabayashi R, Ishikura S, Nishimura Y, Tahara M. Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.Oral Oncol. 2024 Oct:157:106976. doi: 10.1016/j.oraloncology.2024.106976. Epub 2024 Aug 6.


    https://pubmed.ncbi.nlm.nih.gov/39111143/

  29. Mizumoto M, Furukawa T, Yui M, Iritani K, Tatehara S, Inokuchi G, Teshima M, Shinomiya H, Kimura H, Kiyota N, Sasaki R, Nibu KI. A Case of Olfactory Neuroblastoma Developing Bilateral Retropharyngeal Lymph Node Metastasis 14-years After Skull Base Surgery.Kobe J Med Sci. 2024 Jun 3;70(2):E56-E60. doi: 10.24546/0100489917.


    https://pubmed.ncbi.nlm.nih.gov/38936878/

  30. Mizusawa J, Ogawa G, Terada M, Ishiki H, Kikawa Y, Kiyota N. Statistical Analysis Methods and Reporting of Patient-Reported Outcomes in Randomized Controlled Trials for Cancer Conducted in Japan: A Systematic Review.Cureus. 2024 May 21;16(5):e60804. doi: 10.7759/cureus.60804. eCollection 2024 May.


    https://pubmed.ncbi.nlm.nih.gov/38910767/

  31. Yui M, Matsuno Y, Furukawa T, Teshima M, Shinomiya H, Kiyota N, Nomura T, Miyawaki D, Sasaki R, Nibu KI. Oncological Outcomes of Concurrent Chemoradiotherapy and Surgical Treatment for Patients With T3 Hypopharyngeal Cancer: A Single-Center Retrospective Analysis.Cureus. 2024 Jun 17;16(6):e62553. doi: 10.7759/cureus.62553. eCollection 2024 Jun.


    https://pubmed.ncbi.nlm.nih.gov/38894937/

  32. Imamura Y, Kiyota N, Tahara M, Kodaira T, Hayashi R, Nishino H, Asada Y, Mitani H, Iwae S, Nishio N, Onozawa Y, Hanai N, Ohkoshi A, Hara H, Monden N, Nagaoka M, Minami S, Kitabayashi R, Sasaki K, Homma A; Head, Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG). Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.Oral Oncol. 2024 Jul:154:106868. doi: 10.1016/j.oraloncology.2024.106868. Epub 2024 May 30.


    https://pubmed.ncbi.nlm.nih.gov/38820889/

  33. Seno S, Iwashita K, Kajiwara A, Sasaki R, Furukawa T, Teshima M, Shinomiya H, Kiyota N, Lynch R, Yoshida K, Ishihara T, Miyawaki D, Nibu KI, Sasaki R. Targeting Anterior Commissure Involvement with Hyperfractionated Radiotherapy for T1-T2 Squamous Cell Carcinoma of the Glottic Larynx.Cancers (Basel). 2024 May 12;16(10):1850. doi: 10.3390/cancers16101850.


    https://pubmed.ncbi.nlm.nih.gov/38791929/

  34. Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna H. Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.Eur J Cancer. 2024 May:203:114038. doi: 10.1016/j.ejca.2024.114038. Epub 2024 Mar 30.


    https://pubmed.ncbi.nlm.nih.gov/38579517/

  35. Singer S, Sykiotis G, Al-Ibraheem A, Pinto M, Iakovou I, Østhus AA, Hammerlid E, Locati LD, Gamper EM, Arraras JI, Jordan S, Buettner M, Engesser D, Taylor K, Canotilho R, Ioannidis G, Husson O, Gama RR, Fanetti G, Moss L, Inhestern J, Andry G, Rimmele H, Kiyota N. The impact of electronic versus paper-based data capture on data collection logistics and on missing scores in thyroid cancer patients.Endocrine. 2024 May;84(2):635-645. doi: 10.1007/s12020-023-03628-9. Epub 2023 Dec 16.


    https://pubmed.ncbi.nlm.nih.gov/38103143/

  36. Kiyota N. Patients with head and neck cancer unfit for cisplatin-what next?.Lancet Oncol. 2024 Dec;25(12):1513-1514. doi: 10.1016/S1470-2045(24)00597-7. Epub 2024 Nov 14.


    https://pubmed.ncbi.nlm.nih.gov/39551067/

  37. Ohji G, Funakoshi Y, Yakushijin K, Matsutani T, Sasaki T, Kusakabe T, Matsumoto S, Koyama T, Nagatani Y, Kurata K, Kimbara S, Kiyota N, Minami H. Analysis of B-cell receptor repertoire to evaluate the immunogenicity of SARS-CoV-2 RBD mRNA vaccine: MAFB-7256a (DS-5670d).Front Immunol. 2024 Oct 7:15:1468760. doi: 10.3389/fimmu.2024.1468760. eCollection 2024.


    https://pubmed.ncbi.nlm.nih.gov/39434885/

  38. Shimoyama R, Imamura Y, Uryu K, Mase T, Ohtaki M, Ohtani K, Shiragami M, Fujimura Y, Hayashi M, Shinozaki N, Minami H. Analysis of thromboembolism and prognosis in metastatic pancreatic cancer from the Tokushukai REAl‑world data project.Mol Clin Oncol. 2024 Aug 7;21(4):73. doi: 10.3892/mco.2024.2771. eCollection 2024 Oct.


    https://pubmed.ncbi.nlm.nih.gov/39170627/

  39. Yamamoto K, Hirakawa Y, Matsumoto S, Yakushijin K, Minami H. Near-triploidy with four Philadelphia chromosomes in adult B-lymphoblastic leukemia with BCR::ABL1 fusion. Int J Lab Hematol. 2024 Dec;46(6):988-990. doi: 10.1111/ijlh.14327. Epub 2024 Jun 17


    https://pubmed.ncbi.nlm.nih.gov/38887856/

  40. Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Maruyama D, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Kato H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results.Haematologica. 2024 Oct 1;109(10):3357-3362. doi: 10.3324/haematol.2023.283992.


    https://pubmed.ncbi.nlm.nih.gov/38841789/